← Chewy overview
Chewy IncCHWY

Why is Chewy (CHWY) moving?

Q3 2026
▼3▲1

Chewy's mixed quarter: sales beat but outlook cut, JPMorgan downgrade sinks shares

  • Q2 revenue and EPS beat, guidance raised Chewy's second-quarter revenue rose 7.3% and earnings per share beat at $0.36, prompting management to raise guidance. Autoship subscriptions reached 84.6% of sales, adding 208,000 net customers, showing loyal demand.

    This positive operational update is a key new driver of the stock's mixed performance in August.

  • 2026 growth outlook cut, organic growth slows Chewy lowered its full-year 2026 growth outlook, with organic growth slowing to 5.7% from 7.7%. EBITDA guidance midpoint was also reduced, partly due to one-time items, signaling weaker future profitability.

    This is a new negative development that directly weighs on investor expectations and the stock price.

  • JPMorgan downgrade and 11% share drop JPMorgan downgraded Chewy to Neutral, citing an unsustainable tariff benefit, and the stock fell 11%. The downgrade reflects concerns that recent gains may not last, adding selling pressure.

    This analyst action and sharp price decline are central new events driving the stock in August.

  • Chewy+ fee cut and shelf registration raise risks A cut to the Chewy+ membership fee may pressure margins, while a new shelf registration increases the risk of future share dilution. These moves could hurt profitability and existing shareholders.

    These new company-specific actions add to the negative pressures on the stock this period.

August 2026
▼3▲1

Chewy's mixed quarter: sales beat but outlook cut, JPMorgan downgrade sinks shares

  • Q2 revenue and EPS beat, guidance raised Chewy's second-quarter revenue rose 7.3% and earnings per share beat at $0.36, prompting management to raise guidance. Autoship subscriptions reached 84.6% of sales, adding 208,000 net customers, showing loyal demand.

    This positive operational update is a key new driver of the stock's mixed performance in August.

  • 2026 growth outlook cut, organic growth slows Chewy lowered its full-year 2026 growth outlook, with organic growth slowing to 5.7% from 7.7%. EBITDA guidance midpoint was also reduced, partly due to one-time items, signaling weaker future profitability.

    This is a new negative development that directly weighs on investor expectations and the stock price.

  • JPMorgan downgrade and 11% share drop JPMorgan downgraded Chewy to Neutral, citing an unsustainable tariff benefit, and the stock fell 11%. The downgrade reflects concerns that recent gains may not last, adding selling pressure.

    This analyst action and sharp price decline are central new events driving the stock in August.

  • Chewy+ fee cut and shelf registration raise risks A cut to the Chewy+ membership fee may pressure margins, while a new shelf registration increases the risk of future share dilution. These moves could hurt profitability and existing shareholders.

    These new company-specific actions add to the negative pressures on the stock this period.

Latest
▲2▼1

Chewy beats and raises outlook, but growth slowdown and capital moves weigh

  • Q2 earnings beat and raised guidance Chewy reported Q2 EPS of $0.36, nearly double the $0.18 expected, and raised full-year revenue and profit outlook. Autoship sales rose 9.3% to $2.82B, and 208,000 net active customers were added. This shows the core business is still growing and profitable, supporting the stock.

    This is the most important new event: a strong earnings beat and raised guidance that directly boosts investor confidence.

  • Organic growth slows and EBITDA guidance midpoint cut Excluding acquisitions, organic growth decelerated to 5.7% from 7.7% in Q1. The EBITDA beat included one-time items, and the midpoint of full-year EBITDA guidance was lowered slightly. This suggests the underlying business is slowing, which pressures the stock.

    This is the key counterweight: despite the headline beat, underlying growth is slowing and guidance quality is questioned.

  • Chewy Health and vet clinics drive growth Chewy Health delivered triple-digit revenue growth, and Vet Care clinics are scaling with strong economics. Management sees pet health as a $50B market and expects $50M in AI savings by 2027. This expands higher-margin services and supports long-term growth.

    This is a major new growth driver highlighted by management and analysts, showing where future profits will come from.

  • Chewy+ membership fee cut and shelf registration Chewy cut its Chewy+ annual fee to $59 from $79 to attract more subscribers, which could boost loyalty but may pressure near-term margins. It also filed a shelf registration, giving it flexibility to raise capital for acquisitions, which could dilute shareholders. These moves are strategic but carry uncertainty.

    These are new capital and pricing actions that could affect future growth and shareholder value, with both positive and negative implications.

▲2▼2

Chewy's growth slows, AI savings rise, but Wall Street turns cautious

  • Chewy cuts 2026 growth outlook Chewy lowered its 2026 growth expectations, signaling weaker demand for pet products. This makes future sales look softer and pushes the stock down because investors pay for growth.

    This is the first sign of slowing demand and sets a cautious tone for the period.

  • AI cost savings target raised to $50M Chewy said AI will save $50 million a year by fiscal 2027, up from earlier plans. Lower costs mean higher profits without needing more sales, which supports the stock price.

    This is a new, concrete profit driver that offsets some demand worries.

  • Q2 revenue up 7.3%, vet care and fresh food boom Chewy's second-quarter revenue rose 7.3%, with triple-digit growth in vet clinics and fresh/frozen food. Autoship subscriptions hit 84.6% of sales, showing loyal customers. This beat expectations and points to steady demand.

    This is the key earnings report that shows the business is still growing despite a tough pet market.

  • JPMorgan downgrade and tariff-benefit concerns JPMorgan cut Chewy to Neutral and lowered its price target to $24, warning that a one-time tariff benefit may have flattered earnings. The stock fell 11% as investors worried the profit beat wasn't sustainable.

    This is the latest analyst reaction that explains why the stock dropped even after good results.

Q2 2026
▲2▼2

Chewy cuts sales outlook, buys vet chain, but analysts see margin upside

  • Chewy cuts full-year sales outlook Chewy lowered its fiscal 2026 net sales guidance to $13.40–$13.55 billion from $13.6–$13.75 billion, citing cautious consumer spending and weaker premiumization. This directly reduces expected future revenue, pushing the stock down and making it look cheap on sales.

    This is the main negative force this period, explaining why the stock hit a five-year low valuation.

  • Chewy acquires Modern Animal vet clinics Chewy is buying Modern Animal, a tech-enabled vet care provider, adding about $70 million in 2026 revenue and up to $290 million at steady state. This expands into higher-margin pet healthcare, but integration costs will slightly drag margins this year.

    This is a new strategic move that shifts Chewy into healthcare services, a key growth driver.

  • Analysts back margin-improvement story Major banks like Goldman Sachs and Citi reiterated positive views after strong Q1 EBITDA, pointing to advertising, AI efficiency, and healthcare as margin levers. A fair value estimate of $39.85 implies big upside, though cautious guidance and insider selling temper enthusiasm.

    This shows a shift in analyst sentiment that could support the stock price despite weak sales guidance.

  • Fed rate stance pressures e-commerce The Fed held rates steady and signaled a possible hike, raising funding costs for buy-now-pay-later and consumer credit. A stronger dollar also hurts international revenue. This macro headwind pushed Chewy and other online retailers down.

    This is a new monetary policy development that directly affects Chewy's cost of doing business and consumer spending.

June 2026
▲2▼2

Chewy cuts sales outlook, buys vet chain, but analysts see margin upside

  • Chewy cuts full-year sales outlook Chewy lowered its fiscal 2026 net sales guidance to $13.40–$13.55 billion from $13.6–$13.75 billion, citing cautious consumer spending and weaker premiumization. This directly reduces expected future revenue, pushing the stock down and making it look cheap on sales.

    This is the main negative force this period, explaining why the stock hit a five-year low valuation.

  • Chewy acquires Modern Animal vet clinics Chewy is buying Modern Animal, a tech-enabled vet care provider, adding about $70 million in 2026 revenue and up to $290 million at steady state. This expands into higher-margin pet healthcare, but integration costs will slightly drag margins this year.

    This is a new strategic move that shifts Chewy into healthcare services, a key growth driver.

  • Analysts back margin-improvement story Major banks like Goldman Sachs and Citi reiterated positive views after strong Q1 EBITDA, pointing to advertising, AI efficiency, and healthcare as margin levers. A fair value estimate of $39.85 implies big upside, though cautious guidance and insider selling temper enthusiasm.

    This shows a shift in analyst sentiment that could support the stock price despite weak sales guidance.

  • Fed rate stance pressures e-commerce The Fed held rates steady and signaled a possible hike, raising funding costs for buy-now-pay-later and consumer credit. A stronger dollar also hurts international revenue. This macro headwind pushed Chewy and other online retailers down.

    This is a new monetary policy development that directly affects Chewy's cost of doing business and consumer spending.

▲2▼2

Chewy cuts sales outlook, buys vet chain, but analysts see margin upside

  • Chewy cuts full-year sales outlook Chewy lowered its fiscal 2026 net sales guidance to $13.40–$13.55 billion from $13.6–$13.75 billion, citing cautious consumer spending and weaker premiumization. This directly reduces expected future revenue, pushing the stock down and making it look cheap on sales.

    This is the main negative force this period, explaining why the stock hit a five-year low valuation.

  • Chewy acquires Modern Animal vet clinics Chewy is buying Modern Animal, a tech-enabled vet care provider, adding about $70 million in 2026 revenue and up to $290 million at steady state. This expands into higher-margin pet healthcare, but integration costs will slightly drag margins this year.

    This is a new strategic move that shifts Chewy into healthcare services, a key growth driver.

  • Analysts back margin-improvement story Major banks like Goldman Sachs and Citi reiterated positive views after strong Q1 EBITDA, pointing to advertising, AI efficiency, and healthcare as margin levers. A fair value estimate of $39.85 implies big upside, though cautious guidance and insider selling temper enthusiasm.

    This shows a shift in analyst sentiment that could support the stock price despite weak sales guidance.

  • Fed rate stance pressures e-commerce The Fed held rates steady and signaled a possible hike, raising funding costs for buy-now-pay-later and consumer credit. A stronger dollar also hurts international revenue. This macro headwind pushed Chewy and other online retailers down.

    This is a new monetary policy development that directly affects Chewy's cost of doing business and consumer spending.